menu

Medical Program: Are PARP Inhibitors the Future of Treating Triple-Negative Breast Cancer?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Are PARP Inhibitors the Future of Treating Triple-Negative Breast Cancer?

close
Are PARP Inhibitors the Future of Treating Triple-Negative Breast Cancer?
RestartResume
Choose a format
Media formats available:
Details
Presenters
Comments
  • Sponsored by

  • Overview

    At the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, Dr. Matt Birnholz got a chance to talk with Dr. Hans Petter Eikesdal about the head-turning study on PARP inhibitors he presented at the conference.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Sponsored by

  • Overview

    At the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, Dr. Matt Birnholz got a chance to talk with Dr. Hans Petter Eikesdal about the head-turning study on PARP inhibitors he presented at the conference.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 2/22/20